BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
67.73
-1.39 (-2.01%)
At close: May 26, 2026, 4:00 PM EDT
67.97
+0.24 (0.35%)
After-hours: May 26, 2026, 4:13 PM EDT
BridgeBio Pharma Market Cap
BridgeBio Pharma has a market cap or net worth of $13.27 billion as of May 26, 2026. Its market cap has increased by 100.47% in one year.
Market Cap
13.27B
Enterprise Value
14.70B
1-Year Change
100.47%
Ranking
Category
Stock Price
$67.73
Market Cap Chart
Since June 27, 2019, BridgeBio Pharma's market cap has increased from $3.32B to $13.27B, an increase of 299.60%. That is a compound annual growth rate of 22.21%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 22, 2026 | 13.54B | -8.16% |
| Dec 31, 2025 | 14.74B | 184.24% |
| Dec 31, 2024 | 5.19B | -26.16% |
| Dec 29, 2023 | 7.02B | 516.56% |
| Dec 30, 2022 | 1.14B | -53.61% |
| Dec 31, 2021 | 2.46B | -71.83% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jun 27, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Genmab | 16.43B |
| Jazz Pharmaceuticals | 14.83B |
| Ascendis Pharma | 14.70B |
| Summit Therapeutics | 12.97B |
| Ionis Pharmaceuticals | 12.59B |
| Exelixis | 12.52B |
| Axsome Therapeutics | 12.11B |
| Madrigal Pharmaceuticals | 11.97B |